RxDoctor Payments Data

Marlene Lindsay

Adult Health · Orlando, FLNPI 1336163823

Payments from drug & device makers

$4,086in general payments, 2019–2025

Across 145 payments — averaging $28.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$877
  • Abbott$828
  • AbbVie$220
  • Novo Nordisk$205
  • Lilly USA, LLC$168
  • plus $698 from 16 others

What the payments were for

  • Food & beverage$4,086100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,086 in reported general payments places this provider in the 85th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide112$116,133
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$74,379
EliquisApixaban44$49,972
FarxigaDapagliflozin Propanediol34$41,265
LinzessLinaclotide35$31,097
JardianceEmpagliflozin13$21,379
MounjaroTirzepatide17$20,463
XareltoRivaroxaban17$19,580
Tresiba Flextouch U-200Insulin Degludec14$12,159
Tresiba Flextouch U-100Insulin Degludec18$8,632
Olmesartan Medoxomil69$7,767
VascepaIcosapent Ethyl15$6,991
Humalog Kwikpen U-200Insulin Lispro11$6,319
Rosuvastatin Calcium149$6,294
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$6,087

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$205$116,133112 claims
GSKTrelegy Ellipta, Breo Ellipta$877$78,59393 claims
PfizerEliquis$132$49,97244 claims
AstraZenecaFarxiga, Symbicort$1,089$45,37651 claims
AbbVieLinzess$220$31,09735 claims
Boehringer IngelheimJardiance$125$21,37913 claims
Lilly USA, LLCMounjaro$168$20,46317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,237 adult health providers in Florida.

Other adult health in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →